Market Research Report
Global Cancer Immunotherapy Drugs Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022
|Published by||Occams Business Research & Consulting Pvt. Ltd.||Product code||374053|
|Published||Content info||140 Pages
Delivery time: Inquiry
|Global Cancer Immunotherapy Drugs Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022|
|Published: October 1, 2016||Content info: 140 Pages||
The global cancer immunotherapy market is expected to reach $119.39 Billion by 2022 from $61.9 Billion in 2014, at a CAGR of 14.0% during 2016 to 2022. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.
The major driver for the global cancer immunotherapy market is increasing prevalence of cancer.
In 2016, estimation of cancer cases are 1,685,210 which are diagnosed in USA and around 595,690 people will die from cancer .The number of people living beyond the cancer diagnosis reached nearly $14.5 million in 2014 and expected to rise to almost 18 million in year 2022. National expenditures for cancer care in USA could reach up to $157 Billion by 2022. By year 2030, the new breast cancer cases in females in USA are estimated to increase about 441,000 that accounts incremental by 50% as per today. The percentage of new cancer cases of women falling in ages 70-84 is expecting to increase from 24% to 35%. By the end of year 2022, expected number of new cancer cases in the USA will rise about 25% in men which would be more than $1 million cases per year, and by about 22% in women that to be more than 900,000 cases per year. By 2016, among children, an estimation of 10,380 are to be diagnosed with cancer and 1,250 will die from it
The global cancer immunotherapy market has been segmented based on type, application, and end user. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immune modulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR during 2016 to 2022. The high growth in this segment is primarily attributed to the high success rate of these inhibitors. On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others. The lung cancer segment is expected to grow at the highest CAGR during the forecast period. The high growth in this segment can be attributed to the increasing prevalence of this type of cancer and rising demand for advanced treatment options. On the basis of end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The rise in healthcare spending has resulted in the increasing use of immunotherapeutic drugs in hospitals
North America dominates the cancer immunotherapy market in 2016, owing to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity. However, the RoW region is expected to witness the highest CAGR during the forecast period. The high growth in this segment is centered at Latin America, the Middle East, and Africa.
The major players in this market include Amgen, AstraZeneca, F. Hoffman La-Roche Ltd., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company , Janssen Global Services, LLC , Merck,Novartis and Pfizer . Acquisitions, Mergers and key players are key strategies for any market to grow. In May 2016, Pfizer Inc. and Anacor Pharmaceuticals, Inc have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value of approximately $5.2 billion.